<DOC>
	<DOCNO>NCT00679367</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , melphalan dexamethasone , work different way stop growth abnormal plasma cell , either kill cell stop dividing . Biological therapy , lenalidomide , may stimulate immune system different way stop abnormal plasma cell grow . Giving melphalan together lenalidomide dexamethasone may effective treatment primary systemic amyloidosis . PURPOSE : This phase II trial study side effect well give melphalan together lenalidomide dexamethasone work treat patient primary systemic amyloidosis .</brief_summary>
	<brief_title>Melphalan , Lenalidomide , Dexamethasone Treating Patients With Primary Systemic Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine tolerability safety melphalan , lenalidomide , dexamethasone , term toxicity , patient primary systemic amyloidosis . - To determine hematologic response rate patient treat regimen . Secondary - To assess organ response patient treat regimen . OUTLINE : Patients receive oral lenalidomide daily day 1-21 , oral melphalan daily day 1-4 , oral dexamethasone day 1 , 8 , 15 , 22 . Treatment repeat every 28 day 12 month absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 3 month disease progression annually thereafter .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary systemic amyloidosis PATIENT CHARACTERISTICS : Not pregnant Negative pregnancy test Able tolerate anticoagulation regimen ( e.g. , 325 mg aspirin per day , therapeutic warfarin , low molecular weight heparin ) PRIOR CONCURRENT THERAPY : Recovered prior therapy Permanent stable side effects/changes allow Prior chemotherapy , thalidomide , lenalidomide , steroid amyloidosis allow More 4 week since prior concurrent cytotoxic chemotherapy radiotherapy No secondary familial amyloidosis No multiple myeloma ( â‰¥ 30 % plasma cell bone marrow biopsy lytic bone lesion ) No prior cumulative dos oral melphalan &gt; 200 mg No one prior course highdose melphalan stem cell transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>